Latest market authorization supports the safety and effectiveness of DaVitri for consistent, high-quality vitrification

Overture Life, the innovator modernizing IVF to optimize reproductive freedom, announces the launch of its DaVitri platform for fertility preservation for Brazil’s in vitro fertilization (IVF) clinics after being cleared for commercial use as a class I medical device by the nation’s National Health Surveillance Agency (ANVISA). This latest marketing authorization makes Brazil the sixth country in South and Central America where DaVitri can be used to automate vitrification, following another recent launch in Peru. Embryologists in the two countries now join counterparts in Panama, Chile, Dominican Republic, and Argentina in improving the quality and consistency of the delicate vitrification steps, using DaVitri to help standardize processes and, ultimately, reduce the number of IVF cycles required to have a healthy baby.

“We thank the regulators at ANVISA for their thorough review of DaVitri’s technical, performance, and safety data,” said Hans Gangeskar, CEO of Overture Life. “ANVISA’s reputation for stringent review not only offers assurance to those in Brazil seeking to utilize IVF, but further supports our belief that widespread use of the automated DaVitri device will usher in a new era for quality, accessible reproductive healthcare.”

Overture’s mission is to develop and deploy cutting-edge technology to bring the largely manual, outdated approaches common in IVF into the modern era. This includes the use of AI, automation, metabolomics, and microfluidics to ensure that prospective mothers can access the same high-quality fertility care regardless of income, geography, or insurance status. In particular, the tabletop DaVitri could eventually enable vitrification at a specialist’s office, making IVF easier to access anywhere in the world.

“We have been using the DaVitri system since June 2024 to automate vitrification. It increases our efficiency and makes our work more reproducible and safer for patients and physicians,” said Dr. Jorge Castillo Baso, a specialist in gynecology and obstetrics and a founding partner of Ferticlinic and Fertidonors in Panama. “It improves the consistency of results and eliminates variability caused by human intervention, where errors can occur. It also frees up our embryologists' workload, allowing Ferticlinic to perform more procedures without compromising quality.”

About Overture Life

Overture Life integrates engineering, reproductive medicine, and regulatory-grade validation to modernize embryology lab procedures, particularly fertility preservation and embryo handling, in ways that lower repeated cycles, increase throughput, and reduce the overall cost of IVF. With R&D in Spain and active U.S. operations, including a CLIA-licensed laboratory for non-invasive embryo selection, Overture unites robotics, analytics, and clinical rigor to deliver tools that clinics and patients can trust. The company’s DaVitri platform aims to boost reliability and consistency in IVF, giving women and families worldwide more control over their fertility timelines. Overture’s backers include Overwater Ventures, GV (formerly Google Ventures), Khosla Ventures, Octopus Ventures and others committed to advancing the future of fertility.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250508137244/en/